Our first adult patient has received transfusion of blood plasma from a donor who has recovered from coronavirus (COVID-19), as part of a clinical trial looking at potential treatments for the virus.
A patient at the Royal Manchester Children’s Hospital (RMCH) was the first in the UK to receive a convalescent plasma transfusion, after being selected through the RECOVERY COVID-19 research study.
Our first patient has participated in the RUXCOVID research trial, which is testing whether the drug ruxolitinib could be a potential treatment for COVID-19 (coronavirus).
Our first patient has taken part in an interventional research trial testing potential treatments for people with severe COVID-19 infection, being cared for in an Intensive Care Unit.
Our first patient has taken part in the PRIEST study, a research trial aiming to optimise the triage of people using the emergency care system during the COVID-19 (coronavirus) pandemic.
Our first patient has taken part in a research trial testing whether SNG001 – a drug treatment administered via a nebuliser – could be a potential treatment for COVID-19 (coronavirus).